Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that trichoscopy using anisotrichosis criteria was 75% sensitive and 61.54% specific in diagnosing early female pattern hair loss in women without visible hair thinning.

This study found that chronic telogen effluvium is a distinct condition from female pattern hair loss, with different pathogenic mechanisms observed in histomorphometric analyses.

This review concluded that interleukin-17 is involved in the development of female-pattern baldness, suggesting a potential inflammatory role in the condition’s underlying causes.

This review discusses laser/light treatments for pattern hair loss and reports no clinical validation of current devices; experts recommend physician evaluation to exclude other medical conditions.

This study suggests that the HDAC9 gene is a third susceptibility gene for male-pattern baldness, with significant associations found in both German and Australian samples.

This study found that combining fractional radiofrequency microneedling with 5% topical minoxidil improved hair count and thickness more than minoxidil alone in Chinese men with male pattern hair loss.

This study found that women with female pattern hair loss had increased 5α-reductase isozymes and decreased aromatase mRNA levels, potentially affecting their response to treatment.

This study found that a combined pattern of repigmentation was most commonly observed in vitiligo, with a new 'medium spotted' pattern proposed for areas with few hair follicles.

This article addresses diffuse pattern essential syphilitic alopecia as an unusual form of secondary syphilis but provides no new clinical findings.

This study found that certain male pattern baldness subtypes at age 45 are associated with an increased risk of developing colorectal neoplasia.

In this double-blind, randomized controlled trial, researchers found that cow placenta extract lotion was as effective as topical minoxidil 2% in increasing hair count for women with androgenetic alopecia over six months, though the mean increases in hair count were similar for both treatments.

Low androgen levels can still cause female pattern hair loss.

This study found notable differences in finasteride use among the Nordic countries, with higher prevalence in Finland and Sweden compared to Denmark and Norway.

Keith Kaufman reported promising results on treating male-pattern baldness with oral finasteride at the World Congress of Dermatology.

This study found that male pattern baldness was associated with an increased risk of squamous cell carcinoma and basal cell carcinoma, particularly at the scalp.

Finasteride helps female-pattern hair loss.

This study found that mouse skin CD4(+) memory T cells are in equilibrium with the circulation under steady state but increase in specific clusters in response to infection or inflammation.

This study observed that frontal plus moderate vertex baldness at age 45 was associated with a higher risk of aggressive prostate cancer in a large cohort.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.

In their study, Tim Spector and colleagues identified a new genetic association at chromosome 20p11.22 with male-pattern baldness, confirmed by the increased risk when combined with a known androgen receptor gene variant.

This study found that patients with alopecia areata had higher levels of Th17 cells and lower levels of regulatory T cells compared to healthy controls, suggesting an immune imbalance in these patients.

This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.

Lowest effective minoxidil concentration is 1%, but 2% works better for male pattern baldness.

This genome-wide association study identified 71 genetic loci linked to male pattern baldness, with 30 novel loci, explaining 38% of the risk and suggesting shared pathways with lifespan and cancer traits.

This study found that sebaceous glands in bald scalp have greater androgen binding affinity and capacity than those in hairy scalp, possibly contributing to the androgenic response seen in male pattern baldness.

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

High testosterone to epitestosterone ratio in hair could predict male-pattern baldness.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

This study revealed that during fetal development, MITF and Mart-1 expressing melanocytes progress from the dermis to the epidermis and hair follicles, with MITF possibly marking follicular stem cells.